Prostate cancer is the most common cancer among men living in Western nations and now the most common malignancy (with a prevalence near that of bladder cancer) seen in urological clinics in China[@b1]. In the USA, prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer-related death in men, with an estimated 233,000 new cases and 29,480 deaths in 2014[@b2]. In clinical practice, serum prostate-specific antigen (PSA), digital rectal examination (DRE), transrectal ultrasound, and biopsy are widely used for early detection. Although PSA improved prostate cancer detection in the early "PSA era," it has many limitations, especially when PSA values are 4--10 ng/ml (the "gray zone").

In 1999, Bussemakers *et al*. identified the DD3 gene (later also known as prostate cancer antigen 3, or PCA3), which is highly expressed in prostatic tumors[@b3]. A new diagnostic method uses polymerase chain reaction (PCR) to detect the over-expression of PCA3 mRNA in urine. This non-invasive urine biomarker has been evaluated in many clinical studies, in several of which it was combined with other markers to improve the diagnostic accuracy in order to further rule out aggressive cancer at biopsy. In 2012, the US Food and Drug Administration (FDA) approved the PROGENSA PCA3 assay, the first molecular test to help determine the need for repeat prostate biopsies in men with a previous negative biopsy (U.S. Food and Drug Administration Summary of Safety and Effectiveness Data: PROGENSA PCA3 Assay, 2012. Available at [www.accessdata.fda.gov/cdrh_docs/pdf10/P100033b.pdf&U.S](http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100033b.pdf&U.S). Food and Drug Administration Medical Devices: PROGENSA PCA3 Assay, 2012. Available at [www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294907.htm](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294907.htm)).

We consider the current clinical evidence in investigating the diagnostic value of PCA3 in prostate cancer with both initial and repeat biopsy.

Methods
=======

This meta-analysis was performed in accordance with PRISMA[@b4] guidelines, which prefer reporting items from systematic reviews and meta-analyses.

Search strategy and study selection
-----------------------------------

A comprehensive, computerized literature search was performed in PubMed and Embase for work published through December 2014 using a combination of the following key words: \["prostatic neoplasm" or "prostate cancer"\] AND \["PCA3" or "prostate cancer antigen3" or "dd3" or "upm3" or "aptima pca3"\] AND \["diagnosis" or "sensitivity and specificity"\]. Then, the reference sections of the identified publications were searched to identify additional potentially relevant articles. Studies included in our meta-analysis had to meet the following criteria: (1) case-control or cohort design; (2) diagnostic test using PCA3 itself or in combination with other biomarkers; and (3) prostate biopsy as the gold standard.

Data extraction and quality assessment
--------------------------------------

Data were extracted independently by 2 authors (Y.C. and C.L.) and then crosschecked. For each study, the following information was collected: last name of the first author, publication year, study design and ethnicity, age, PSA, sample size and the values of true positive (TP), false positive (FP), false negative (FN), true negative (TN), and area under the curve (AUC) (with 95% CI) if available. When more than one article was published using the same population, we selected the most recent or most informative report. Disagreements between the two authors were resolved by consensus. The quality of the selected studies was assessed using quality assessment of diagnostic accuracy studies (QUADAS)[@b5]. The QUADAS tool consists of a set of 14 questions, each of which is scored as yes, no, or unclear.

Statistical analysis
--------------------

For each study, 2 × 2 tables for each test with TP, FP, FN, and TN results were extracted from the original scientific articles. Pooled estimates of sensitivity (Se) and specificity (Sp) and their 95% confidence intervals were calculated as the main outcome measures. Forest plots were used, and methodological heterogeneity was assessed during selection.

The threshold effect is a characteristic source of heterogeneity in the meta-analysis of diagnostic tests and arises when the included studies use different cut-off points to define a positive result of a diagnostic test. The analysis of the diagnostic threshold was assessed through the receiver operating characteristic (ROC) plane and Spearman's correlation coefficient The ROC plane is the graphic representation of the pairs of Se and Sp, and it characteristically shows a curvilinear pattern if the threshold effect exists. Statistical heterogeneity was measured using the χ^**2**^ test and *I^2^* scores. The *I^2^* score was used as a measure of the inconsistency between studies in the meta-analysis and was interpreted as low (25--50%), moderate (51--75%), or high (\>75%).

Data were analyzed using the statistical software package Metadisc, version 1.4. The results were synthesized and represented graphically in a forest plot. If heterogeneity was found, the meta-analysis was performed using a random effects model. If there was evidence of the threshold effect, the studies were combined to create a summarized ROC curve (SROC), to calculate an additional measurement of the accuracy of the technique (Q^\*^) and to obtain the AUC.

Results
=======

A total of 1,648 relevant references were obtained in our systematic search. The results and study selection process are shown in [Fig. 1](#f1){ref-type="fig"}. There were 245 articles requiring full-text review, and 46 studies were included in the meta-analysis[@b6][@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51]. In addition, one study (by Hensen *et al*.[@b52]) that focused on combined initial prostate cancer biopsy in a North American and European multi-center cohort that overlapped in two studies[@b13][@b34] was included in the stratified analysis of initial biopsy. Additionally, the study by Scattoni *et al*.[@b48] included initial and repeat biopsy groups that were treated as two data sets. The quality of the selected studies on diagnostic testing was moderate to high according to the QUADAS scale ([Table 1](#t1){ref-type="table"}).

Based on the studies described above, we retrieved data from 12,295 patients with PCA3 test results and prostate biopsy, of whom 4,225 were diagnosed with prostate cancer. All studies presented the sensitivity, specificity, and cut-off points (25 studies had a cut-off of PCA3 = 35), and most studies presented the ROC curve ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). Among the 46 trials, most were performed in the U.S. and Europe; 5 were performed in Asia ([Table 1](#t1){ref-type="table"}).

The indices of diagnostic validity obtained from the 2 × 2 tables showed that sensitivity ranged from 46.9% to 95%, and specificity ranged from 21.6% to 100%. In the 40 articles that presented the AUC, it ranged from 0.57 to 0.85. A meta-analysis was conducted using the 46 articles mentioned above. The ROC space showed a curvilinear trend, and Spearman's correlation coefficient was 0.612 (P \< 0.001), which suggests the existence of a threshold. There was a high degree of heterogeneity in sensitivity (χ2 = 271.39, P \< 0.001), specificity (χ2 = 735.87, P \< 0.001), and diagnostic OR (Cochran-Q = 137.22, P \< 0.001); consequently, the diagnostic indices were calculated using a random effects model. Using a forest plot, the overall sensitivity, specificity, positive likelihood ratio , negative likelihood ratio and diagnostic OR were 0.65 (95% CI 0.63--0.66) ([Fig. 2](#f2){ref-type="fig"}), 0.73 (95% CI 0.72--0.74) ([Fig. 3](#f3){ref-type="fig"}), 2.23 (95% CI: 1.91--2.62), 0.48 (95% CI: 0.44--0.52) and 5.31 (95% CI: 4.19--6.73) ([Fig. 4](#f4){ref-type="fig"}), respectively. We used a summary SROC to aggregate data and obtained a symmetrical curve with an AUC of 0.748 ([Fig. 5](#f5){ref-type="fig"}) that represented the technique's diagnostic performance.

Discussion
==========

The clinical value for prostatic cancer diagnoses was not conclusive. According to the European Association of Urology and the National Comprehensive Cancer Network guidelines, the need for prostate biopsy should be determined on the basis of PSA and/or a suspicious DRE[@b53][@b54]. However, serum PSA levels can be elevated in benign conditions, and only 25% of men who are clinically suspected of having PCa will have a positive biopsy[@b55][@b56]. Thus, other biomarkers with high sensitivity and specificity are needed for screening.

The PCA3 gene was mapped to chromosome 9q21--22, in antisense orientation within intron 6 of the Prune homolog 2 gene (PRUNE2 or BMCC1), spanning a region of approximately 25 kb[@b57][@b58]. Ferreira *et al*. found that PCA3 may modulate PCa cell survival, and PCA3 expression is androgen-regulated via activation of AR-mediated signaling[@b59]. PCA3 is a non-coding, prostate-specific mRNA that is highly over-expressed in 95% of PCa cells, with a median 66-fold up-regulation compared with adjacent non-neoplastic cells[@b60]. Because PCA3 does not encode a protein, the only molecule that can be tested is the mRNA; PCA3 mRNA can be measured in urine sediment after DRE. A PCA3 score is the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. Although we currently have a good understanding of the role of PCA3 in tumor genes and tissues, the picture is incomplete.

Several studies have indicated that the PCA3 test is useful in reducing the number of negative biopsies[@b34][@b39][@b51], and more recently the FDA approved the PROGENSA PCA3 assay as a new test for prostate cancer.

Recent advances have included biomarkers such as HPG-1, AMACR, STAMP1, TMPRSS2, ERG, PHI, and P2PSA[@b31][@b42][@b48][@b61][@b62][@b63]. Some studies have assessed their efficacy by detecting these markers alone or in combination. Although several biomarkers may have specificity that is the same as or higher than that of PCA3, the non-invasive nature of the urine PCA3 test, which is performed after prostate massage, and its good diagnostic performance may make the PCA3 test a better choice for prostate cancer screening.

The current meta-analysis shows the clinical usefulness of this tumor marker in detecting prostate cancer with initial or repeat biopsy. We synthesized the current knowledge about early diagnosis of prostate cancer with PCA3 determination in urine samples. According to the data from 46 studies analyzed, specificity is 0.65 (range 47--95%), which is not adequate; sensitivity is 0.73, which is somewhat lower, and had a minimum value of 21%. The AUC of 0.75 obtained in the SROC curve suggests acceptable performance of the diagnostic test.

In the stratified analysis, a forest plot of initial biopsy showed overall sensitivity and specificity of 0.65 (95% CI 0.63--0.67) and 0.82 (95% CI 0.81--0.83), respectively, and a symmetrical curve with an AUC of 0.80 (95% CI 0.78--0.82) ([Table 2](#t2){ref-type="table"}). With repeat biopsy, these values dropped to 0.58 (95% CI 0.55--0.62), 0.69 (95% CI 0.67--0.71), and 0.68 (95% CI 0.67--0.70) ([Table 2](#t2){ref-type="table"}), respectively. Mixed biopsy showed values of 0.66 (95% CI 0.64--0.68), 0.68 (95% CI 0.67--0.69), and 0.75 (95% CI 0.74--0.76) ([Table 2](#t2){ref-type="table"}), respectively. These results suggest that PCA3 is potentially more suitable for initial prostate biopsy than repeat prostate biopsy. When we stratified the studies by PCA3 cut-off value, the overall sensitivity, specificity, and symmetrical curve AUC values were 0.63 (95% CI 0.62--0.65), 0.74 (95% CI 0.73--0.75), 0.74 (95% CI 0.73--0.76), respectively, for studies with a cut-off value ≠ 35 ([Table 2](#t2){ref-type="table"}) and 0.70 (95% CI 0.68--0.73), 0.67 (95% CI 0.65--0.69), and 0.77 (95% CI 0.75--0.79), respectively, for studies with a cut-off value = 35 ([Table 2](#t2){ref-type="table"}). Although the latter group showed better diagnostic performance, it has a greater range and more variable outcomes. This observation supports a cut-off of 35 for the standard value and clinical practice of many institutions. Comparing study designs, the overall sensitivity, specificity, and symmetrical curve AUC values were 0.63 (95% CI 0.61--0.66), 0.88 (95% CI 0.87--0.90), and 0.82 (95% CI 0.79--0.85) ([Table 2](#t2){ref-type="table"}), respectively, for case-control studies and 0.65 (95% CI 0.63--0.66), 0.73 (95% CI 0.72--0.74), and 0.75 (95% CI 0.74--0.76) ([Table 2](#t2){ref-type="table"}), respectively, for prospective studies. Because case-control studies typically enroll fewer patients and have greater heterogeneity, their quality is not as good as that of prospective studies.

Our meta-analysis has some limitations. First, the study numbers and the heterogeneity of their approaches influence the accuracy. Although the gold standard (biopsy) was used in all studies, the patient selection, lack of blinding, and different PCA3 cut-off values caused heterogeneity. Second, a potential publication bias may exist, although we tried to avoid this bias by expanding our searches in different databases and by conducting rigorous screening for studies. We evaluated the quality of the articles according to the QUADAS questionnaire. The quality of the studies in terms of diagnostic testing was moderate to high. The relatively small number of trials included in this meta-analysis and significant heterogeneity across the studies may make our conclusion conservative.

According to the current meta-analysis, the PCA3 test shows good diagnostic performance. However, it requires further exploration in well-designed and appropriately-powered trials to determine intermediate and long-term outcomes. Long-term observational studies of health outcomes are also subject to biases.
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###### Methodological quality of the 46 studies according to the QUADAS questionnaire.

  Study            Year     Country/region     Patients   Test   Result                                   
  --------------- ------ -------------------- ---------- ------ --------- ----- --------- --------- ----- -----
  Hessels          2003    Netherlands/Eur       Yes      Yes      No      Yes     Yes       No      No    Yes
  Fradet           2004         Canada           Yes      Yes      Yes     Yes     Yes       No      Yes   Yes
  Tinzel           2004      Austria/Eur         Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Groskopf         2006           US             Yes      Yes      Yes     Yes     No      Unclear   No    Yes
  van Gils         2007    Netherlands/Eur       Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  van Gils         2007    Netherlands/Eur       Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Marks            2007       US, Canada         Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Deras            2008       US, Canada         Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Haese            2008         Europe           Yes      Yes      Yes     Yes     Yes     Unclear   Yes   Yes
  Laxman           2008           US             Yes      Yes      Yes     Yes     No      Unclear   Yes   Yes
  Ouyang           2009           US             Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Shappell         2009           US             Yes      Yes      No      Yes     No      Unclear   No    Yes
  Wang             2009           US             Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Mearini          2009       Italy/Eur          Yes      Yes      Yes     Yes     No        Yes     No    Yes
  Henderson        2010         UK/Eur           Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Aubin            2010           US             Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Auprich          2010         Europe           Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Morotel          2010       Spain/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Nyberg           2010       Sweden/Eur         Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Roobol           2010    Netherlands/Eur       Yes      Yes      Yes     Yes     Yes     Unclear   Yes   Yes
  Rigau            2010       Spain/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Shen             2010      China/Asian         Yes      Yes      Yes     Yes     No      Unclear   Yes   Yes
  Schilling        2010      Germany/Eur         Yes      Yes      Yes     Yes   Unclear     Yes     No    Yes
  Rubio-Briones    2011       Spain/Eur          Yes      Yes      Yes     Yes     Yes     Unclear   Yes   Yes
  Adam             2011      South Africa        Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Cao              2011      China/Asian         Yes      Yes    Unclear   Yes     No        Yes     No    Yes
  Ochiai           2011         Japan            Yes      Yes      Yes     Yes     Yes     Unclear   Yes   Yes
  Perdona          2011       Italy/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Taille           2011         Europe           Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Babera           2012       Italy/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   No
  CF Ng            2012      China/Asian         Yes      Yes      Yes     Yes     Yes       Yes     Yes   No
  Crawford         2012           US             Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Pepe             2012       Italy/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Pepe             2012       Italy/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Sciarra          2012       Italy/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Wu               2012           US             Yes      Yes      Yes     Yes     No        Yes     No    Yes
  Ferro            2013         Europe           Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Goode            2013           US             Yes      Yes      Yes     Yes     No        Yes     No    Yes
  Ochiai           2013         Japan            Yes      Yes      Yes     Yes     Yes     Unclear   Yes   Yes
  Stephan          2013      Germany/Eur         Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Perdona'         2013   Italy/EurCaucasian     Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Salagierski      2013       Poland/Eur         Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Scattoni         2013       Italy/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes
  Chevli           2013          USA             Yes      Yes      Yes     Yes     No        Yes     Yes   Yes
  Giuseppe         2014       Italy/Eur          Yes      Yes      Yes     Yes     Yes       No      Yes   Yes
  Francesco        2014       Italy/Eur          Yes      Yes      Yes     Yes     Yes       Yes     Yes   Yes

###### PCA3 stratified analysis.

                  Data sets    Sensitivity (95% CI)   Specificity (95% CI)   Diagnostic OR (95% CI)   *I^2^, %*\*     AUC (95% CI)
  --------------- ----------- ---------------------- ---------------------- ------------------------ ------------- -------------------
  Total           43                                                                                                         
  Design                                                                                                           
   Case-control   8             0.63 (0.61--0.66)      0.88 (0.87--0.90)      10.36 (5.51--21.25)        36.9       0.82 (0.79--0.85)
   Prospective    39            0.65 (0.63--0.66)      0.73 (0.72--0.74)       5.31 (4.19--6.73)         70.5       0.75 (0.74--0.76)
  biopsy                                                                                                           
   Initial\*      14            0.65 (0.63--0.67)      0.82 (0.81--0.83)       8.14 (4.78--13.86)        51.8       0.80 (0.78--0.82)
   Repeated\*     11            0.58 (0.55--0.62)      0.69 (0.67--0.71)       3.19 (2.62--3.83)           0        0.68 (0.67--0.70)
   Mixed          22            0.66 (0.64--0.68)      0.68 (0.67--0.69)       5.13 (3.99--6.60)         76.9       0.75 (0.74--0.76)
  cut-off value                                                                                                    
   Equal 35       26            0.63 (0.62--0.65)      0.74 (0.73--0.75)       4.75 (3.42--6.60)         64.1       0.74 (0.73--0.76)
   Not equal 35   21            0.70 (0.68--0.73)      0.67 (0.65--0.69)       6.22 (4.62--8.37)         62.6       0.77 (0.76--0.79)

[^1]: These authors contributed equally to this work.
